Media stories about XBiotech (NASDAQ:XBIT) have been trending somewhat positive on Thursday, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. XBiotech earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.8171450347683 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

XBiotech (XBIT) traded up $0.25 during mid-day trading on Thursday, reaching $4.62. 116,400 shares of the company were exchanged, compared to its average volume of 213,322. XBiotech has a 12 month low of $2.77 and a 12 month high of $20.18.

TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact XBiotech (XBIT) Share Price” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at

About XBiotech

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response.

Insider Buying and Selling by Quarter for XBiotech (NASDAQ:XBIT)

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with's FREE daily email newsletter.